HealthQuartzabout 2 hours ago
Abivax raises $920M for U.S. drug launch
1 min read
Abivax CEO stated the $920 million raise enables the company to independently launch its bowel disease drug in the U.S. market. The funding supports a solo commercial rollout without a partner.
Level
Hype check
Tap to vote and see what everyone thinks.
